 |
Life Technologies (India) Pvt Ltd. 306, Agarwal City Mall, opposite M2K Pitampura, Delhi-110034 (India) Tel # +91-11-4220-8000; 4220-8111; 4220-8222 Fax# +91-11-4220-8444, Mobile# +91-98105-21400 Email# [email protected] |
Neurodegenerative Disease-related Compound Library
Cat. No.: HY-L086
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.
MCE offers a unique collection of 1839 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.
MCE Neurodegenerative Disease-related Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 1804 compounds supplied in 10 mM solution and 35 compounds supplied in 2 mM solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, and 2 mM for compounds with solubility between 2 mM and 10 mM.
Size (Pre-dissolved Solution or Solid)
- 30 μL/well Solution
(10 mM and 2 mM Pre-dissolved Solution) - 50 μL/well Solution
(10 mM and 2 mM Pre-dissolved Solution) - 100 μL/well Solution
(10 mM and 2 mM Pre-dissolved Solution) - 2 × 100 μL/well Solution
(10 mM and 2 mM Pre-dissolved Solution)
Publications Citing Use of MCE Compound Libraries
• Nat Med. 2017 Apr 7;23(4):405-408. [Abstract]
• Chem Rev. 2020 Oct 28;120(20):11616-11650. [Abstract]
• Circulation. 2022 Apr 12;145(15):1154-1168. [Abstract]
• J Med Virol. 2021 Jun 1. [Abstract]
• Nat Commun. 2018 Apr 26;9(1):1677. [Abstract]
• Nat Commun. 2020 Sep 4;11(1):4417. [Abstract]
• Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]
• EMBO Mol Med. 2021 Dec 20;e14608. [Abstract]
• J Biomed Sci. 2018 Aug 2;25(1):60. [Abstract]
• Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
• Cell Rep. 2017 Jul 25;20(4):999-1015. [Abstract]
• J Cheminform. 2018 Jul 31;10(1):34. [Abstract]
• J Med Chem. 2018 Jan 11;61(1):360-371. [Abstract]
• J Invest Dermatol. 2021 Sep 14;S0022-202X(21)01672-9. [Abstract]
• Life Sci. 2020 Oct 1;258:118228. [Abstract]
• Front Pharmacol. 2020 Nov 11;11:580407. [Abstract]
• Epigenetics Chromatin. 2020 Aug 3;13(1):31. [Abstract]
• Sci Rep. 2017 Oct 16;7(1):12881. [Abstract]
• ACS Chem Biol. 2016 Dec 16;11(12):3400-3411. [Abstract]
• ACS Chem Biol. 2016 May 20;11(5):1245-54. [Abstract]
• Biol Reprod. 2017 Nov 1;97(5):671-687. [Abstract]
• SLAS Discov. 2020 Sep;25(8):895-905. [Abstract]
• Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303. [Abstract]
• In Vitro Cell Dev Biol Anim. 2016 Apr;52(4):488-96. [Abstract]
• Acta Med Iran. 2017 Mar;55(3):200-208. [Abstract]
• bioRxiv. 2021 Jun 15;2021.05.15.444128. [Abstract]
• Chem Biol. 2015 Aug 20;22(8):1144-55. [Abstract]
• Faculty of Medicine, Medicum. University of Helsinki. 2017 Dec.
| Description & Advantages | ||||||
|
• A unique collection of 1839 compounds for high throughput screening (HTS) and high content screening (HCS). • Targets include Amyloid-β, Dopamine Receptor, COMT, LRRK2, 5-HT Receptor, Monoamine Oxidase, nAChR, Histamine Receptor, etc. • A useful tool for exploring the mechanism of neurodegenerative diseases and looking for new treatments. • Bioactivity and safety confirmed by clinical trials or preclinical research. Some have been approved by FDA. • Structurally diverse, medicinally active, and cell permeable. • Detailed compound information with structure, IC50, and brief introduction. • High purity and quality validated by NMR and LC/MS. • All compounds are in stock and continuously updated. |
||||||
| Product Details | ||||||
|
• Formulation:A collection of 1839 neurodegenerative disease-related compounds supplied as pre-dissolved Solutions or Solid • Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty. 384-well plate: the first two columns and the last two columns are left empty. Compounds with different concentrations or dissolved in different solvents will be put on separate plates. This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know. • Container:96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode • Storage:-80°C • Shipping:Blue ice |
||||||
| Composition | ||||||
| Neurodegenerative Disease-related Compound Library (Source: MedChem Express) | ||||||
|---|---|---|---|---|---|---|
|
||||||
|
||||||
|
||||||
| Documentation | ||||||